Kyung-Hun Lee
About
Kyung-Hun Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Kyung-Hun Lee has authored 216 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Oncology, 79 papers in Pulmonary and Respiratory Medicine and 46 papers in Cancer Research. Recurrent topics in Kyung-Hun Lee's work include Advanced Breast Cancer Therapies (32 papers), HER2/EGFR in Cancer Research (30 papers) and Breast Cancer Treatment Studies (27 papers). Kyung-Hun Lee is often cited by papers focused on Advanced Breast Cancer Therapies (32 papers), HER2/EGFR in Cancer Research (30 papers) and Breast Cancer Treatment Studies (27 papers). Kyung-Hun Lee collaborates with scholars based in South Korea, United States and Ethiopia. Kyung-Hun Lee's co-authors include Seock‐Ah Im, Do‐Youn Oh, Sae‐Won Han, Yung‐Jue Bang, Tae‐Yong Kim, Tae‐You Kim, Sara A. Hurvitz, Johannes Ettl, Hope S. Rugo and Joanne L. Blum and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Kyung-Hun Lee
209 papers receiving 5.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kyung-Hun Lee South Korea | 35 | 4.1k | 2.0k | 1.6k | 1.5k | 706 | 216 | 6.0k | ||
| Hagen F. Kennecke Canada | 33 | 3.6k 0.9× | 1.4k 0.7× | 1.4k 0.8× | 1.9k 1.2× | 686 1.0× | 156 | 5.5k | ||
| Daniele Generali Italy | 42 | 3.1k 0.8× | 1.7k 0.9× | 2.5k 1.5× | 2.1k 1.4× | 429 0.6× | 232 | 6.2k | ||
| Alessandro Morabito Italy | 40 | 4.8k 1.2× | 3.4k 1.7× | 1.7k 1.0× | 1.7k 1.1× | 443 0.6× | 217 | 7.2k | ||
| Helen Mackay Canada | 41 | 2.9k 0.7× | 1.2k 0.6× | 2.9k 1.8× | 1.3k 0.8× | 787 1.1× | 185 | 7.1k | ||
| Young Kwang Chae United States | 40 | 3.1k 0.8× | 1.9k 0.9× | 2.6k 1.6× | 1.7k 1.1× | 777 1.1× | 274 | 6.4k | ||
| Hellmut Samonigg Austria | 41 | 4.0k 1.0× | 1.2k 0.6× | 1.9k 1.2× | 2.9k 1.9× | 750 1.1× | 118 | 6.6k | ||
| Alexandra Léary France | 38 | 3.5k 0.8× | 973 0.5× | 2.0k 1.2× | 1.3k 0.8× | 879 1.2× | 280 | 7.5k | ||
| Steven G. DuBois United States | 47 | 2.0k 0.5× | 2.7k 1.4× | 2.4k 1.5× | 1.5k 1.0× | 856 1.2× | 281 | 7.4k | ||
| Anke Reinacher‐Schick Germany | 30 | 3.1k 0.8× | 1.1k 0.6× | 1.3k 0.8× | 1.4k 0.9× | 756 1.1× | 158 | 4.7k | ||
| Pär‐Ola Bendahl Sweden | 44 | 3.3k 0.8× | 1.4k 0.7× | 2.7k 1.7× | 3.0k 1.9× | 644 0.9× | 181 | 6.7k |
Countries citing papers authored by Kyung-Hun Lee
Since
Specialization
Citations
This map shows the geographic impact of Kyung-Hun Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyung-Hun Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyung-Hun Lee more than expected).
Fields of papers citing papers by Kyung-Hun Lee
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kyung-Hun Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyung-Hun Lee. The network helps show where Kyung-Hun Lee may publish in the future.
Co-authorship network of co-authors of Kyung-Hun Lee
This figure shows the co-authorship network connecting the top 25 collaborators of Kyung-Hun Lee. A scholar is included among the top collaborators of Kyung-Hun Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyung-Hun Lee. Kyung-Hun Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kim, Kyubo, Yong Bae Kim, Sun Ha Paek, et al.. (2024). Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery. Radiotherapy and Oncology. 199. 110461–110461.
2.
Park, Yeon Hee, Kyung-Hun Lee, Gun Min Kim, et al.. (2024). Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.. Journal of Clinical Oncology. 42(17_suppl). LBA1002–LBA1002.
3.
Kim, Hong Kyu, Seho Park, Min Hyuk Lee, et al.. (2023). Multidisciplinary Shared Decision Making for Fertility Preservation in Young Women With Breast Cancer. Journal of Breast Cancer. 26(6). 582–582.
4.
Lee, Dae‐Won, Kyung Hae Jung, Kyung-Hun Lee, et al.. (2023). Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. European Journal of Cancer. 197. 113456–113456.
5.
Koh, Jiwon, Dae‐Won Lee, Han Suk Ryu, et al.. (2023). HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results. Breast Cancer Research. 25(1). 154–154.
6.
Chang, Euijin, Song Yi Park, Dae‐Won Lee, et al.. (2022). Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment. The Oncologist. 27(12). e931–e937.
7.
Lee, Kyung-Hun, Joohyuk Sohn, Annabel Goodwin, et al.. (2021). Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. Cancer Research and Treatment. 53(4). 1084–1095.
8.
Lin, Ching‐Hung, Yoon Sim Yap, Kyung-Hun Lee, et al.. (2019). Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. JNCI Journal of the National Cancer Institute. 111(12). 1298–1306.
9.
Yeo, Winnie, Takayuki Ueno, Ching‐Hung Lin, et al.. (2019). Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Research and Treatment. 177(3). 549–559.
10.
Jeon, Seung Hyuck, Kyung Hwan Shin, Jin Ho Kim, et al.. (2018). Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy. Breast Cancer Research and Treatment. 172(3). 619–626.
11.
Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763.
12.
Suh, Dong Hoon, Miseon Kim, Kyung-Hun Lee, et al.. (2018). Major clinical research advances in gynecologic cancer in 2017. Journal of Gynecologic Oncology. 29(2). e31–e31.
13.
Nam, Ah-Rong, Ji‐Won Kim, Ji Eun Park, et al.. (2016). Src as a Therapeutic Target in Biliary Tract Cancer. Molecular Cancer Therapeutics. 15(7). 1515–1524.
14.
Ock, Chan‐Young, Ju‐Hee Bang, Tae-Yong Kim, et al.. (2015). The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.. PubMed Central. 5(11). 3376–88.
15.
Ock, Chan-Young, Keun‐Wook Lee, Jin Won Kim, et al.. (2015). Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. Clinical Cancer Research. 21(11). 2520–2529.
16.
Kim, Ji‐Won, Jee Hyun Kim, Seock‐Ah Im, et al.. (2013). HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 72(1). 109–115.
17.
Kim, Ji‐Won, Jee Hyun Kim, Seock‐Ah Im, et al.. (2013). Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. Cancer Chemotherapy and Pharmacology. 72(5). 1023–1029.
18.
Han, Sae‐Won, Hwang-Phill Kim, Jong-Yeon Shin, et al.. (2013). Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. PLoS ONE. 8(5). e64271–e64271.
19.
Min, Ahrum, Seock‐Ah Im, Young‐Kwang Yoon, et al.. (2013). RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. Molecular Cancer Therapeutics. 12(6). 865–877.
20.
Han, Sae‐Won, Tae‐You Kim, Yoon Kyung Jeon, et al.. (2006). Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research. 12(8). 2538–2544.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hagen F. Kennecke Breakdown of academic impact, for papers by Daniele Generali Breakdown of academic impact, for papers by Alessandro Morabito Breakdown of academic impact, for papers by Helen Mackay Breakdown of academic impact, for papers by Young Kwang Chae Breakdown of academic impact, for papers by Hellmut Samonigg Breakdown of academic impact, for papers by Alexandra Léary Breakdown of academic impact, for papers by Steven G. DuBois Breakdown of academic impact, for papers by Anke Reinacher‐Schick Breakdown of academic impact, for papers by Pär‐Ola Bendahl